WAYNE, PA — Palvella Therapeutics, Inc. has appointed Matthew E. Korenberg as its new Chief Financial Officer, a move that underscores the company’s commitment to advancing its rare disease treatment pipeline. Effective immediately, Korenberg joins Palvella with over 27 years of experience in biotech leadership and healthcare investment banking.
Wes Kaupinen, Founder and CEO of Palvella, expressed enthusiasm about the new addition: “I am thrilled to welcome Matt to the Palvella senior leadership team. Matt’s proven track record in public company corporate finance and strategy, operations, and capital markets will be instrumental to Palvella as we advance our rare disease pipeline and progress our lead product candidate QTORIN™ rapamycin to potential regulatory approvals and U.S. commercialization.”
Korenberg brings a wealth of experience from his previous roles, including his tenure as President and Chief Operating Officer at Ligand Pharmaceuticals Inc., where he also served as CFO. His career also includes founding NeuroCircuit Therapeutics, a company specializing in drugs for genetic brain disorders, and a long stint at Goldman Sachs in biotech and pharmaceutical investment banking.
On his new role, Korenberg stated, “I am excited to join Palvella at such a dynamic time. The combination of a dedicated leadership team, patented QTORIN™ platform technology, and promising late-stage rare disease pipeline position the company well for growth.”
Palvella Therapeutics is focused on becoming a leader in developing therapies for serious, rare genetic skin diseases. With Korenberg’s expertise, the company aims to navigate its transition to a public entity while addressing significant unmet medical needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.